Alzheimer Dementia Diagnosis - Overview
With the number of aging populations increasing worldwide, dementia is fast becoming a critical healthcare issue. Diagnosing dementia is both challenging and time consuming. A major challenge has been the prompt and timely detection of the disease. While all major pathological changes in the brain occur early on, diagnosis is rarely clear until a time when most of the damage has already been done. Physicians face additional challenges when administering proper treatment options and monitor for efficacy. With only cognitive test results and the subjective evaluation of clinical symptoms as a basis for diagnosis, the need for an accurate biomarker that can support early detection is more urgent than ever. The EEG Cholinergic IndexTM provides valuable information for this purpose.
This evidence based neurodiagnostic tool is a potent biomarker with unprecedented powerful capacities of differential diagnostic aid for dementia. Despite the lack of clear golden standards for most of dementias, the irregular nature of vascular dementia, the uncommonness of fronto-temporal dementia and the labile nature of depression the underlying neurophysiology of different groups seem to produce a reliably different signature in the EEG signal that give separations from ~75% to ~95% depending on classifiers.
Early diagnosis of Alzheimer´s
Diagnosing MCI patients - although some remain stable MCI, many develop AD later. Early signs of AD are visible in electrophysiology before confirmed by clinical diagnosis.
Differential diagnostic of Dementia
The EEG dementia analysis is a potent neurodiagnostic biomarker for differential diagnosis of dementia comorbidities. The physiological nature of dementia syndromes allows our neurodiagnostic aiding tool to demonstrate separation between different types of dementia, including MCI, AD and Lewy body dementia.
Avoid improper medication
We demonstrate decisive and confident diagnostic of Lewy body dementia that is an important assessment of serious or even fatal side-effects that improper medication has on DLB patients.
Monitor disease of dementia and treatment effect
Monitor the evolution of dementia and/or estimate treatment effect. We can track the progress of AD, as well as influence of Cholinesterase inhibitor treatment and bring additional help to pharmacological development.
The algorithm allows ruling out and/or depicting impairment component due to depression.
EEG Cholinergic IndexTM
Drugs used in the treatment of Alzheimer's disease and other dementias are mainly cholinesterase inhibitors, which are thought to enhance the function of the cholinergic system. The pharmacodynamic effects of these medicines have traditionally been measured only by cognitive tests and caregiver’s reports, and, until now, there have been no direct biological means of evaluating the effects of any treatment. The EEG changes seen in Alzheimer’s disease and other dementias reflect the cholinergic response of the drugs in the brain. Using a Cholinergic Index based on EEG recordings, Sigla offers an objective method to evaluate and monitor the effects of cholinergic drugs, helping to support appropriate and effective ongoing treatment.